

## **Cardinal Health Targets Biotechnology and Sterile Life Sciences Market and Names Pharmaceutical Manufacturing Veteran To Lead Effort**

### **Creation of Biotechnology and Sterile Life Sciences business underscores company's strategy to expand breadth of health care offerings**

DUBLIN, Ohio, Feb. 12, 2003 /PRNewswire-FirstCall/ -- Cardinal Health, Inc. [CAH](#), the leading provider of products and services supporting the health care industry, today announced the formation of the Biotechnology and Sterile Life Sciences business. The new business brings together a full complement of existing biotechnology and sterile technology and services, furthering Cardinal Health's strategy to expand the breadth of its offering to pharmaceutical and biotechnology companies.

Cardinal Health named Frank Leo president of the new business, which will offer a full range of services -- from drug discovery to the commercial manufacture of sterile pharmaceuticals and biotechnology-based products -- and will operate under the Pharmaceutical Technologies and Services group of Cardinal Health.

Combined with other services offered by Pharmaceutical Technologies and Services, Biotechnology and Sterile Life Sciences provides a seamless transition from protein drug development to commercial scale manufacturing and offers customers the added benefit of access to other Cardinal Health services such as contract sales, logistics, specialty distribution of commercial products and medical education.

"This represents another great opportunity for pharmaceutical and biotechnology companies to rely on Cardinal Health to bring new drugs to market expeditiously and cost effectively," said George Fotiades, president and chief executive officer of Life Sciences Products and Services, who oversees Pharmaceutical Technologies and Services. "It also demonstrates our commitment to aggressively expanding and evolving to meet the needs of our growing customer base."

Among the recent advancements in that evolution is the opening last month of a full-service, state-of-the-art contract pharmaceutical development facility in Somerset, N.J., to help bring new drugs to market quickly and cost effectively. The \$80 million center is a multi-disciplinary facility for the formulation and science of oral drugs. Cardinal Health also is in the process of expanding its operations in San Diego to provide comprehensive clinical- scale biotech drug development and is investing in its Raleigh, N.C., operations for additional commercial scale biologics manufacturing.

Creation of Biotechnology and Sterile Life Sciences is the culmination of strategic acquisitions and investment activities, which together form a world- class offering to biotechnology customers. These offerings include:

- \* Blow/fill/seal technology (formerly Automatic Liquid Packaging Inc.),
- \* Sterile liquid and lyophilization clinical and commercial manufacturing (formerly SP Pharmaceuticals),
- \* Commercial scale production of cell culture in Raleigh, N.C.,
- \* Biotechnology analytical and development services in San Diego (part of the former Magellan Laboratories), and
- \* **Biotechnology/cell line creation/gene expression (Gala Design).**

"Small- and medium-size biotechnology companies are looking to capitalize on Cardinal Health's proprietary technologies, as well as its tremendous scale and staying power, which will give them creative alternatives and independence they may not enjoy through more traditional relationships

with pharmaceutical companies," Leo said. "This is especially crucial in today's climate, in which it is difficult to raise capital. For all these reasons, we've put together a team of dedicated individuals and built a solid infrastructure for Biotechnology and Sterile Life Sciences with a single goal of providing world-class services to our customers."

Leo has 25 years of experience in the sterile technologies industry. He came to Cardinal Health in 1999, when the company acquired Automatic Liquid Packaging, and has been overseeing the Sterile Technologies business of Cardinal Health ever since. At Automatic Liquid Packaging, he held a variety of positions over an 18-year period, including vice president, R&D, and, later, chief operating officer.

#### About Cardinal Health

Cardinal Health, Inc. ( [www.cardinal.com](http://www.cardinal.com) ) is the leading provider of products and services supporting the health care industry. Cardinal Health companies develop, manufacture, package and market products for patient care; develop drug-delivery technologies; distribute pharmaceuticals, medical- surgical and laboratory supplies; and offer consulting and other services that improve quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal Health employs more than 50,000 people on five continents and produces annual revenues of more than \$44 billion. Cardinal Health is ranked #23 on the current Fortune 500 list and was named one of "The World's Best" companies by Forbes magazine in 2002.

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports and exhibits to those reports, and include (but are not limited to) the costs, difficulties, and uncertainties related to the integration of acquired businesses, the loss of one or more key customer or supplier relationships, changes in the distribution outsourcing patterns for health-care products and/or services, the costs and other effects of governmental regulation and legal and administrative proceedings, and general economic conditions. Cardinal Health undertakes no obligation to update or revise any forward-looking statements.

© 2003 PRNewswire